scholarly journals Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

2021 ◽  
Author(s):  
Ke Xuan Li ◽  
Gisele Diendéré ◽  
Jean‐Philippe Galanaud ◽  
Nada Mahjoub ◽  
Susan R. Kahn
Keyword(s):  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Narrative Review ◽  
Postthrombotic Syndrome ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

scholarly journals Modern view on the therapy of chronic venous insufficiency with micronized purified flavonoid fraction

2020 ◽  
Vol 19 (4) ◽  
pp. 2592
Author(s):  
H. M. Kurginyan ◽  
V. V. Raskin
Keyword(s):  
Pharmaceutical Industry ◽  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Population Studies ◽  
Varicose Veins ◽  
Venous Diseases ◽  
High Prevalence ◽  
Important Direction ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

The high prevalence of varicose veins has been established in numerous population studies. Currently, guidelines have been developed for the treatment of patients with varicose veins for various stages of chronic venous insufficiency. Nevertheless, despite the use of modern drugs, leg compression, surgical and other interventions, it is not possible to completely reverse the symptoms of venous insufficiency. The article is devoted to the analysis of micronized flavonoid purified fraction. The development of modern drugs for chronic venous diseases is an important direction in medicine. The creation of a drug pool manufactured InRussiais a priority in the development of the country’s pharmaceutical industry. The review presents data on the study of Detravenol (Russia), which is a combination of diosmin and hesperidin (micronized purified flavonoid fraction).

scholarly journals Management of chronic venous insufficiency of the lower extremities

2018 ◽  
pp. 36-41
Author(s):  
M. N. Kudykin
Keyword(s):  
Mechanism Of Action ◽  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Clinical Manifestations ◽  
Lower Extremities ◽  
Venous Diseases ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

The article presents up-to-date information about epidemiology, pathogenesis and clinical manifestations of chronic venous diseases and chronic venous insufficiency of the lower extremities. It discusses the mechanism of action of various phlebotrophic drugs intended for the treatment of symptoms of chronic venous diseases and chronic venous insufficiency and describes the advantages of micronized purified flavonoid fraction for the treatment of all clinical classes of chronic venous diseases.

scholarly journals Varicose Vein And Ecchymosis: A Case Report

10.3823/2508 ◽  
2017 ◽  
Vol 10 ◽  
Author(s):  
Ertan Yetkin ◽  
Selçuk Öztürk ◽  
Mehmet ILeri
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Clinical Practice ◽  
Female Patient ◽  
Varicose Vein ◽  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Lower Extremities ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

Assessment of varicose vein and chronic venous insufficiency and making a differential diagnosis in patients suffering from a variety of sign and symptoms is sometimes a big challenge in daily clinical practice. Here, we present a female patient with varicose vein symptoms and ecchymosis on her lower extremities. Several irregular shaped ecchymotic lesions on both extremities in different stage of healing with deep purple have been treated by using micronized purified flavonoid fraction.

Therapeutic equivalence of two dosage forms of a micronized flavonoid fraction in patients with chronic venous insufficiency

1996 ◽  
Vol 57 (10) ◽  
pp. 757-766 ◽  
Author(s):  
Henri Boccalon ◽  
Catherine Salvadori ◽  
Dominique Benedittini ◽  
Dominique Steru ◽  
Claire Vilain
Keyword(s):  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Dosage Forms ◽  
Therapeutic Equivalence ◽  
Flavonoid Fraction

scholarly journals CHRONIC VENOUS INSUFFICIENCY

10.23856/3217 ◽  
2019 ◽  
Vol 32 (1) ◽  
pp. 131-136
Author(s):  
Antoni Stadnicki ◽  
Martin Rusnák ◽  
Anna Stadnicka
Keyword(s):  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Varicose Veins ◽  
Chronic Venous Disease ◽  
Postthrombotic Syndrome ◽  
Venous Disease ◽  
Compression Stockings ◽  
Venous Leg Ulcer ◽  
Color Flow ◽  
Clinical Disorder

Chronic venous insufficiency (CVI) is a common, but underdiagnozed clinical disorder associated with a variety of signs and symptoms. The presence of leg edema in association  with varicose veins, and venous leg ulcer in later disease stages defines the disease. The pathogenesis of chronic venous disease  is based on venous reflux, obstruction, or a combination thereof.  Prior postthrombotic syndrome   is one of risk factor for CVI which may explain observed  prevalence of thrombophilia in CVI. Color flow duplex ultrasound is the gold standard for nearly all diagnostic issues related to chronic venous disease. Compression stockings are the mainstay for conservative management. Earlier use of venous ablation therapy should be considered in symptomatic patients with superficial tortuous vein

The Beneficial Augmentative Effect of Micronised Purified Flavonoid Fraction (MPFF) on the Healing of Leg Ulcers: An Open, Multicentre, Controlled, Randomised Study

1999 ◽  
Vol 14 (4) ◽  
pp. 151-157 ◽  
Author(s):  
W. Gliński ◽  
B. Chodynicka ◽  
J. Roszkiewicz ◽  
T. Bogdanowski ◽  
B. Lecewicz-Toruń ◽  
...  
Keyword(s):  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Venous Ulcer ◽  
Control Group ◽  
Cure Rate ◽  
Randomised Study ◽  
Venous Ulcers ◽  
The Mean ◽  
Flavonoid Fraction ◽  
The Cost

Objective: To determine the increase in healing rate of venous ulcer in patients receiving a micronised purified flavonoid fraction (MPFF) as supplementation to standard local care. Design: A randomised, open, controlled, multicentre study. Setting: Departments of Dermatology and University Outpatients Clinics. Patients: One hundred and forty patients with chronic venous insufficiency and venous ulcers. Intervention: Patients received standard compressive therapy plus external treatment alone or 2 tablets of MPFF daily in addition to the above treatment for 24 weeks. Main outcome measure: Healing of ulcers and their reduction in size after 24 weeks of treatment. Results: The percentage of patients whose ulcers healed completely was found to be markedly higher in those receiving MPFF in addition to standard external and compressive treatment than in those treated with conventional therapy alone (46.5% vs 27.5%; p<0.05, OR = 2.3, 95% CI 1.1–4.6). Ulcers with diameters <3 cm were cured in 71% of patients in the MPFF group and in 50% of patients in the control group, whereas ulcers between 3 and 6 cm in diameter were cured in 60% and 32% of patients ( p<0.05), respectively. The mean reduction in ulcer size was also found to be greater in patients treated with MPFF (80%) than in the control group (65%) ( p<0.05). The cost-effectiveness ratio (cost per healed ulcer) in the MPFF group was €1026.2 compared with €1871.8 in the control group. Conclusions: These results indicate that MPFF significantly improves the cure rate in patients with chronic venous insufficiency.

Sign in / Sign up

Export Citation Format

Share Document